New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Lignende værker

• Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
  af: Tartaglione, Immacolata, et al.
  Udgivet: (2020)
• Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
  af: Taher, Ali T., et al.
  Udgivet: (2018)
• Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis
  af: Taher, Ali T., et al.
  Udgivet: (2019)
• Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
  af: Taher, Ali T, et al.
  Udgivet: (2014)
• Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
  af: Taher, Ali T, et al.
  Udgivet: (2016)